Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) ((RESPONSE))

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Incyte Corporation
ClinicalTrials.gov Identifier:
NCT01243944
First received: November 17, 2010
Last updated: March 12, 2014
Last verified: March 2014
  Purpose

This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of INC424 to Best Available Therapy (BAT) in subjects with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).


Condition Intervention Phase
Polycythemia Vera
Drug: INC424 tablets
Other: Best Available Therapy (BAT)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care

Resource links provided by NLM:


Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • To compare the efficacy of INC424 to Best Available Therapy as assessed by both the absence of phlebotomy eligibility and reduction in spleen volume. [ Time Frame: 32 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the proportion of subjects randomized to INC424 vs. Best Available Therapy achieving both durable absence of phlebotomy eligibility and durable spleen volume reduction. [ Time Frame: 48 Weeks. ] [ Designated as safety issue: No ]
  • To compare the proportion of subjects randomized to INC424 vs. Best Available Therapy achieving complete hematological remission. [ Time Frame: 32 Weeks ] [ Designated as safety issue: No ]
  • To determine the proportion of subjects achieving a durable spleen volume reduction [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • To estimate the proportion of subjects achieving a durable complete hematological remission [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • To estimate the proportion of subjects achieving a durable phlebotomy independence [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • To estimate the duration of both the absence of phlebotomy eligibility and reduction in spleen volume [ Time Frame: Through study completion ] [ Designated as safety issue: No ]
  • To determine the overall clinicohematologic response rate [ Time Frame: 32 Weeks ] [ Designated as safety issue: No ]
  • To estimate the proportion of subjects achieving a durable complete or partial clinicohematologic response [ Time Frame: 48 Weeks ] [ Designated as safety issue: No ]
  • To estimate the duration of the overall clinicohematologic response [ Time Frame: Through study completion ] [ Designated as safety issue: No ]
  • To estimate the proportion of subjects achieving both durable absence of phlebotomy eligibility and durable spleen volume reduction 48 weeks after the response was initially documented [ Time Frame: Through study completion. ] [ Designated as safety issue: No ]
  • Safety and tolerability of INC424 as measured by adverse events, laboratory assessments, physical examination, vital signs, and ECG measurements. [ Time Frame: Through study completion ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: October 2010
Estimated Study Completion Date: September 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INC424 tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Drug: INC424 tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Best Available Therapy
Best Available Therapy (BAT) will be selected by the Investigator for each subject. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs.
Other: Best Available Therapy (BAT)
Best Available Therapy (BAT) will be selected by the investigator for each subject. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs.
Other Names:
  • BAT:
  • 1. Hydroxyurea
  • 2. IFN/PEG-IFN
  • 3. Pipobroman
  • 4. Anagrelide
  • 5. IMIDs
  • 6. Observation only

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria
  • Subjects resistant to or intolerant of hydroxyurea
  • Subjects with a phlebotomy requirement
  • Subjects with a palpable splenomegaly and a spleen volume of greater than or equal to 450 cubic centimeters
  • Subjects with an ECOG performance status of 0, 1 or 2

Exclusion Criteria:

  • Women who are pregnant or nursing
  • Subjects with inadequate liver or renal function
  • Subjects with significant bacterial, fungal, parasitic, or viral infection requiring treatment
  • Subjects with an active malignancy within the past 5 years, excluding specific skin cancers
  • Subjects with known active hepatitis or HIV positivity
  • Subjects who have previously received treatment with a JAK inhibitor
  • Subjects being treated with any investigational agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01243944

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Chandler, Arizona, United States
Scottsdale, Arizona, United States
United States, Arkansas
Jonesboro, Arkansas, United States
United States, California
La Jolla, California, United States
Pomona, California, United States
Sacramento, California, United States
San Diego, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Connecticut
Bridgeport, Connecticut, United States
New Haven, Connecticut, United States
United States, Florida
Boynton Beach, Florida, United States
Ft Meyers, Florida, United States
Jacksonville, Florida, United States
Lake Worth, Florida, United States
Miami, Florida, United States
West Palm Beach, Florida, United States
Winter Park, Florida, United States
United States, Idaho
Boise, Idaho, United States
United States, Illinois
Barrington, Illinois, United States
Chicago, Illinois, United States
Joliet, Illinois, United States
Quincy, Illinois, United States
Springfield, Illinois, United States
United States, Iowa
Sioux City, Iowa, United States
United States, Louisiana
Lafayette, Louisiana, United States
United States, Maine
Scarborough, Maine, United States
United States, Maryland
Baltimore, Maryland, United States
Columbia, Maryland, United States
United States, Massachusetts
Metheun, Massachusetts, United States
United States, Michigan
East Lansing, Michigan, United States
Southfield, Michigan, United States
United States, Minnesota
Duluth, Minnesota, United States
United States, Missouri
Jefferson City, Missouri, United States
Saint Louis, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, Nevada
Henderson, Nevada, United States
United States, New Hampshire
Portsmouth, New Hampshire, United States
United States, New Jersey
East Orange, New Jersey, United States
Morristown, New Jersey, United States
Phillipsburg, New Jersey, United States
Somerville, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Armonk, New York, United States
Lake Success, New York, United States
Mineola, New York, United States
New Rochelle, New York, United States
New York, New York, United States
Valhalla, New York, United States
United States, North Carolina
Goldsboro, North Carolina, United States
United States, North Dakota
Bismarck, North Dakota, United States
United States, Ohio
Canton, Ohio, United States
Cleveland, Ohio, United States
Middletown, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Bethlehem, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Upland, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
Greenville, South Carolina, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Corpus Christi, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Charlottesville, Virginia, United States
Roanoke, Virginia, United States
United States, Washington
Seattle, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Argentina
Buenos Aires, Argentina
Australia
Brisbane, Australia
Frankston, Australia
Parkville, Australia
Belgium
Antwerp, Belgium
Brugge, Belgium
Bruxelles, Belgium
Gent, Belgium
Haine-saint-Paul, Belgium
Leuven, Belgium
Yvoir, Belgium
Canada
Hamilton, Canada
Montreal, Canada
Toronto, Canada
China
Beijing, China
Hangzhou, China
France
Avignon, France
Bayonne, France
Brest cedex, France
Creteil, France
Lens cedex, France
Les Nancy, France
Lille, France
Limoges, France
Nantes, France
Nimes, France
Paris, France
Germany
Aarchen, Germany
Berlin, Germany
Freiburg, Germany
Hamburg, Germany
Jena, Germany
Kiel, Germany
Magdeburg, Germany
Mannheim, Germany
Minden, Germany
Munchen, Germany
Ulm, Germany
Wurburg, Germany
Hungary
Budapest, Hungary
Debrecen, Hungary
Kecskemet, Hungary
Szeged, Hungary
Szolnok, Hungary
Szombathely, Hungary
Italy
Bari, Italy
Bergamo, Italy
Bolonga, Italy
Firenze, Italy
Milano, Italy
Monza, Italy
Napoli, Italy
Orbassano, Italy
Pavia, Italy
Reggio Calabria, Italy
Roma, Italy
Varese, Italy
Vicenza, Italy
Japan
Chiba, Japan
CHO-City, Japan
Maebashi, Japan
Nagoyi, Japan
Osaka, Japan
Tokyo, Japan
Korea, Republic of
Seoul, Korea, Republic of
Netherlands
Enschede, Netherlands
Rotterdam, Netherlands
Russian Federation
Moscow, Russian Federation
St. Petersburg, Russian Federation
Spain
Barcelona, Spain
La Coruna, Spain
La Laguna, Spain
Las Palmas de Gran Canaria, Spain
Madrid, Spain
Majadanonda, Spain
Malaga, Spain
Pamplona, Spain
Salamanca, Spain
Santiago de Compostela, Spain
Valencia, Spain
Thailand
Bangkok, Thailand
Turkey
Ankara, Turkey
Istanbul, Turkey
Izmir, Turkey
United Kingdom
Bournmouth, United Kingdom
Cardiff, United Kingdom
Leeds, United Kingdom
London, United Kingdom
Nottingham, United Kingdom
Sponsors and Collaborators
Incyte Corporation
Novartis Pharmaceuticals
Investigators
Study Director: Srdan Verstovsek, MD,PhD M.D. Anderson Cancer Center
Study Director: Mark Jones, MD Incyte Corporation
  More Information

Additional Information:
No publications provided

Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT01243944     History of Changes
Other Study ID Numbers: CINC424B2301
Study First Received: November 17, 2010
Last Updated: March 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Incyte Corporation:
INCB018424

Additional relevant MeSH terms:
Polycythemia
Polycythemia Vera
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Hydroxyurea
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antisickling Agents
Hematologic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on July 24, 2014